about
Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedureFunctional and therapeutic significance of EZH2 in urological cancersIntegrated Analysis of Long Noncoding RNA and mRNA Expression Profile in Advanced Laryngeal Squamous Cell Carcinoma.Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development.Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma.Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors.USP21 promotes cell proliferation and metastasis through suppressing EZH2 ubiquitination in bladder carcinoma.Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches.Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.Ezh2-dependent therapies in bladder cancer: synthetic lethality.Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription.DNA methylation in urothelial carcinoma.Unmasking molecular profiles of bladder cancer.
P2860
Q33689126-397D46C1-4152-416D-AB49-67B2B1E255ACQ33914244-8AB1AA42-4DF4-48ED-BEA8-3781D1F2AFCFQ36235850-9C9ABFA5-3595-44C5-8ABA-927927E77BCAQ37099828-80097E80-9F6C-4E7C-B0AD-2A06D45260D4Q37630728-0B345790-F15A-4B92-A934-0E5A8D79E2FBQ37745567-657AE814-FF93-47A5-80D0-4A77D9432D17Q38725418-5582F28B-86B7-4923-8C6C-68D796F8BD02Q38949135-444DE165-87C5-44A2-A08C-41F7C5AB4779Q39035829-0BDE9FCA-77CC-4E4D-813D-CB1794FCB80FQ39428933-84438396-145B-4390-828E-627338678A9AQ41790109-DD4796CF-FAE8-44DE-A5EF-FCA80BC89335Q47100757-CEA4979E-C19E-4F50-A22E-3068A429D52DQ48186262-4DDE1FB8-924C-4AF3-9179-AEBB214C4C86Q52694946-B0AF7138-67E7-4B2E-A350-270F691F6480Q53691833-BE77E85F-6A5E-4994-AE67-C43D2C9F96B7Q55427566-49D6A182-3C47-4CC7-B1E0-ABDB35C7EEB7
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@ast
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@en
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@nl
type
label
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@ast
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@en
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@nl
prefLabel
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@ast
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@en
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@nl
P2093
P2860
P921
P3181
P356
P1476
EZH2 in Bladder Cancer, a Promising Therapeutic Target
@en
P2093
Carolina Rubio
Cristina Segovia
Fernando F López-Calderón
Mónica Martínez-Fernández
P2860
P304
27107-27132
P3181
P356
10.3390/IJMS161126000
P407
P5008
P577
2015-11-13T00:00:00Z